MD Anderson demonstrates 97% complete response rate in hairy cell leukemia patients in Phase 2 trial of JNJ cladribine and Roche rituximab
Clinical Design and 10-Year Long-Term Follow-Up Results
This Phase 2 clinical trial (NCT00412594), led by MD Anderson Cancer Center, evaluated the sequential combination therapy of cladribine and rituximab in 139 patients with hairy cell leukemia (HCL), a rare blood cancer. With a long-term follow-up of up to 18.8 years, 133 patients (97% of those evaluated) achieved complete response (CR), demonstrating near-complete remission. Notably, 77% of patients showed negative results in measurable residual disease (MRD) testing, indicating eradication of the disease at its root. These results are considered an innovative milestone, demonstrating not only simple remission but also the potential for long-term cure.
Mechanism of Action and Clinical Significance of Sequential Combination Therapy
The existing standard treatment was the purine analog cladribine monotherapy from Johnson & Johnson (JNJ), but it had a critical limitation of high long-term relapse rates due to residual cancer cells. To address this, researchers introduced a sequential therapy, administering cladribine followed by Roche's CD20-targeted monoclonal antibody rituximab approximately one month later. Cladribine initially reduces the tumor mass (debulking), and rituximab then induces an immune response to eliminate the remaining B-cell-derived cancer cells, creating a complementary mechanism. As a result, this strategy induces a much deeper remission than the existing monotherapy, leading to excellent clinical outcomes in preventing relapse.
Long-Term Survival and Analysis of Treatment Outcomes in Patient Subgroups
The 10-year event-free survival (EFS) rate observed during the long-term follow-up period was 86.7%, and the 10-year overall survival (OS) rate was 91.1%, both very high levels. Serious adverse events (AEs) occurred in only about 20.1% of patients, mainly due to infections, and were found to be well-controlled. Interestingly, the relapse rate was only 3.6% in the newly diagnosed classic HCL patient group, but the HCL variant (HCLv) patient group, which has a poorer prognosis, showed a relapse rate of 40%. This highlights the need for personalized combination therapy or the development of next-generation targeted therapies based on genetic variations.
Changes in Competitive Landscape and Commercial Opportunities in the Off-Label Market
The global market size for hairy cell leukemia treatments is estimated at approximately $175.6 million in 2025, and it is a rare disease market with expected future growth. In the past, AstraZeneca (AZN)'s CD22-targeted immunotoxin lumoxiti decided to withdraw from the market in 2023 due to commercial limitations, leading to changes in the competitive landscape. In addition, Roche's BRAF-targeted therapy vemurafenib is used, but its high price limits patient access. As a result, the sequential combination therapy of generic cladribine and rituximab biosimilars, which are cost-effective due to patent expiration, has become a strong off-label alternative.
This Phase 2 clinical trial's long-term data demonstrates that the sequential combination therapy of generic cladribine and rituximab biosimilars effectively functions as a standard of care (SOC) in the global hairy cell leukemia (HCL) market, which is estimated at approximately $175.6 million in 2025. The 10-year overall survival rate of 91.1% and the complete response rate of 97% set an extremely high clinical hurdle for new drug developers seeking to enter the market after AstraZeneca (AZN)'s lumoxiti withdrawal. From the perspective of investors and researchers, this case validates the commercial viability of a low-risk development portfolio by creating high added value comparable to that of expensive new drugs, using only the optimal combination of existing assets with expired patents. Meanwhile, the 40% relapse rate observed in the extremely poor-prognosis variant patient group (HCLv) reminds us of the need to develop next-generation targeted therapies to replace Roche's zelboraf and other existing BRAF-variant targeted therapies. Ultimately, from a medium- to long-term perspective, this combination therapy is expected to provide biotechnology companies developing rare blood cancer treatments with a clear R&D direction: companion diagnostics-based precision medicine and multi-target combination therapies.
Source: ClinicalTrials.gov (api_ct)